Aug. 12 at 9:10 PM
$ANTX cut my position in 1/2 at
$6.35/sh. now just playing this investment with house money as we await phase 2 pv data in 2027.
fdmc:
$310M (at
$6/sh)
net pro forma cash:
$75M runway into 2029
catalysts: Q4 2026 – Mid-2027: Preliminary efficacy and safety data readouts from the Phase 2 PV sentinel cohorts.
Investment Summary
-- AN2 Therapeutics (ANTX) has transitioned from its legacy focus on treatment-refractory mycobacterial lung disease (MAC) toward a dual-engine value proposition spanning hematology and global health.
-- The company is leveraging its proprietary boron chemistry platform to develop epetraborole for Polycythemia Vera (PV) and AN2-502998 for chronic Chagas disease. By repurposing epetraborole—which already boasts an established Phase 3 safety database—AN2 utilizes a "fast-follower" clinical strategy to challenge injectable incumbents.
-- Shored up by a
$40 Million private placement in March 2026 from elite institutional funds like Vivo and Commodore Capital, AN2 presents a heavily de-risked platform trading at a massive valuation disconnect relative to its multi-billion dollar target markets.
Capital Structure & Valuation (Pro Forma)
-- Fully Diluted Share Count: ~51.10 Million. Calculation includes: 36.02M basic shares outstanding (as of May 7, 2026), 5.79M 2026 pre-funded warrants, 2.95M 2025 pre-funded warrants, and ~6.34M in outstanding stock options.
-- Fully Diluted Market Cap: ~
$306 Million (based on
$6/share).
-- Total Debt:
$0.00 Million (per latest SEC disclosures).
-- Net Pro Forma Cash (as of June 30, 2026): ~
$75 Million. Calculated as the March 31, 2026 cash balance of
$85.30 Million minus 3 months of estimated operational burn through June 30 (
$14.40 Million total at ~
$4.80 Million/month). March 2026 financing -
$40M at
$2.85/sh.
-- Cash Runway: Projected into 2029. Current guidance suggests the company is funded through multiple Phase 2 readouts in PV and Chagas disease, aided by the August 2024 workforce reduction and 2026 capital infusion.
Pipeline & Mechanism of Action
-- Lead Candidate: Epetraborole for Polycythemia Vera (PV). Stage: Phase 2 proof-of-concept initiation expected Q3 2026. Mechanism: Boron-based small molecule inhibiting leucyl-tRNA synthetase (LeuRS), yielding a controlled, red-cell-selective 3-5% reduction in hematocrit (HCT) while sparing platelets and white blood cells. Epetraborole is also being evaluated in an active Phase 2 investigator-initiated trial (IIT) in collaboration with Oregon Health and Sciences University (OHSU).
-- PV Market Opportunity & PYS: The total addressable PV market in the US is estimated at
$1.5 Billion to
$2.0 Billion. Targeting second-line refractory patients, epetraborole's Peak Yearly Sales (PYS) estimate is
$450 Million –
$600 Million in the US and EU, tracking conservatively against Protagonist's broader first-line
$1B+ rusfertide profile.
-- Secondary Candidate: AN2-502998 for Chronic Chagas Disease. Stage: Phase 1 complete (June 4, 2026 data update); Phase 2 proof-of-concept initiation scheduled for late 2026. Mechanism: Orally active inhibitor of CPSF3 (an essential mRNA processing enzyme), achieving a definitive parasitic cure.
-- Chagas Market Opportunity & PYS: Chagas represents a global multi-billion-dollar commercial opportunity, affecting over 300,000 adults in the US and 10 million globally. Modeled after the systemic screening and "test-and-treat" paradigm of Hepatitis C, AN2-502998's commercial PYS estimate is
$300 Million –
$500 Million across developed territories, supplemented by non-dilutive upside from a potential
$100M FDA Priority Review Voucher (PRV).
-- Oncology: Lead program targeting ENPP1 (solid tumors) and PI3Kα. Currently in preclinical stage; expected to advance into clinical development in 2026.
Catalyst Readout Timeline
-- Late 2026: Initiation of the Phase 2 proof-of-concept trial for AN2-502998 in patients with chronic Chagas disease in collaboration with the DNDi.
-- Q1 2027: Preliminary efficacy and safety data readouts from the open-label Phase 2 PV sentinel cohorts, rolling out progressively following trial enrollment start in Q4 2026.
-- Late 2027: Topline results from the active investigator-initiated Phase 2 study of epetraborole in Mycobacterium abscessus lung disease at OHSU.
Competitive Positioning
-- Primary Competitor: Protagonist Therapeutics (PTGX) / Takeda (rusfertide). Rusfertide is a weekly injectable hepcidin mimetic. Protagonist/Takeda also have an oral successor in early development.
-- Secondary Competitors: Eli Lilly (recently acquired Ajax Therapeutics for an oral PV asset) and established therapies like Incyte's Jakafi (ruxolitinib).
-- Positioning: Epetraborole is positioned as the first-in-class oral, red-cell selective therapy. Its competitive advantage lies in the oral tablet form factor, which addresses high patient preference over weekly injections, and its demonstrated ability to reduce HCT by 3-5% in healthy volunteers—a signal not seen as early in competing programs.
-- In the Chagas landscape, AN2-502998 stands uniquely positioned as the potential first FDA-approved therapy for chronic Chagas in adults, utilizing a clinically validated mechanism (CPSF3) mirrored by the recently EMA-approved acoziborole.
Management & Board
-- Eric Easom (CEO/Chairman): Co-founder; former President of Anacor Pharmaceuticals (acquired by Pfizer for
$5.2B); deep expertise in boron chemistry.
-- Lucy Day (CFO): Former lead at various biotech firms; recently transitioned to a part-time role as part of cost-efficiency measures.
-- Sanjay Chanda (CDO): Former Anacor executive with extensive experience in clinical development of boron-based molecules.
Deep Expertise: Led by Eric Easom (CEO) and Michael Alley (Biology), who both hail from Anacor Pharmaceuticals, the pioneers of boron-based drug discovery (acquired by Pfizer for
$5.2B).
-- Board Highlights: Includes representatives from Vivo Capital and Commodore Capital, ensuring strong alignment with institutional investors following the 2026 private placement. Board approved a broad stock option repricing to
$3.91 in March 2026 -- This move aligns management's personal outcomes with shareholders as they approach Phase 2 readouts.
Bull Thesis
-- Immediate Valuation Disconnect: AN2 trades at an Enterprise Value of ~
$132 Million, leaving the newly validated Chagas platform completely unpriced while trading at a severe discount to hematology peers.
-- Breakthrough Chagas Efficacy: The June 4, 2026 data update confirmed 100% durable parasite elimination in naturally infected chronic nonhuman primates (NHPs) alongside zero human dose-limiting toxicities in Phase 1, marking it as the most translationally derisked Chagas candidate in development.
-- High Structural Margin of Safety: Epetraborole’s extensive legacy Phase 3 safety profile mitigates the downstream toxicological failure rates typical of early-stage new chemical entities.
-- Immediate PRV Optionality: A successful Chagas approval unlocks a high-probability Tropical Disease Priority Review Voucher, which commands an open-market cash value of ~
$100 Million.
Bear Thesis
-- Commercial Adoption Hurdles: Replicating a Hepatitis C-style "test-and-treat" commercial market for Chagas disease requires extensive medical awareness campaigns to overcome historical under-screening rates in adults.
-- Emerging Big Pharma Competition: Eli Lilly’s entry into oral PV mechanisms validates the space but exposes AN2 to an aggressive development race against vastly superior commercial resources.
-- Clinical Translation Variables: While HCT reduction has been firmly observed as an incidental marker in healthy cohorts, epetraborole has yet to establish primary therapeutic efficacy in a dedicated, phlebotomy-dependent PV population.
-- Geographic Regulatory Risk: Running the initial Phase 2 PV trial exclusively in India introduces prospective logistical and execution hurdles when seeking FDA validation for a US NDA pathway.
